Natalie Serkova
Concepts (694)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Magnetic Resonance Spectroscopy | 36 | 2014 | 611 | 2.790 |
Why?
| | Cyclosporine | 20 | 2012 | 268 | 2.610 |
Why?
| | Immunosuppressive Agents | 23 | 2013 | 890 | 2.120 |
Why?
| | Sirolimus | 17 | 2013 | 276 | 1.740 |
Why?
| | Magnetic Resonance Imaging | 25 | 2024 | 3566 | 1.660 |
Why?
| | Piperazines | 6 | 2009 | 350 | 1.220 |
Why?
| | Pyrimidines | 8 | 2017 | 470 | 1.220 |
Why?
| | Metabolomics | 11 | 2021 | 678 | 1.140 |
Why?
| | Energy Metabolism | 14 | 2019 | 922 | 1.100 |
Why?
| | Glucose | 14 | 2021 | 1020 | 1.100 |
Why?
| | Contrast Media | 6 | 2017 | 467 | 1.040 |
Why?
| | Brain | 14 | 2024 | 2668 | 1.040 |
Why?
| | Antineoplastic Agents | 15 | 2022 | 2129 | 1.000 |
Why?
| | Liver | 12 | 2020 | 1943 | 0.890 |
Why?
| | Biomarkers | 14 | 2019 | 4149 | 0.880 |
Why?
| | Animals | 101 | 2025 | 36940 | 0.870 |
Why?
| | Neoplasms | 14 | 2017 | 2671 | 0.860 |
Why?
| | Drug Resistance, Neoplasm | 6 | 2017 | 801 | 0.840 |
Why?
| | Neoplasms, Experimental | 3 | 2020 | 176 | 0.820 |
Why?
| | Reperfusion Injury | 11 | 2014 | 279 | 0.720 |
Why?
| | Rats | 31 | 2015 | 5647 | 0.660 |
Why?
| | Biomarkers, Tumor | 10 | 2020 | 1276 | 0.650 |
Why?
| | Proton Magnetic Resonance Spectroscopy | 2 | 2019 | 20 | 0.650 |
Why?
| | Multimodal Imaging | 1 | 2020 | 113 | 0.640 |
Why?
| | Protein Kinase Inhibitors | 10 | 2018 | 916 | 0.630 |
Why?
| | Cell Line, Tumor | 27 | 2025 | 3412 | 0.620 |
Why?
| | Ferrosoferric Oxide | 3 | 2019 | 27 | 0.610 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 5 | 2014 | 122 | 0.590 |
Why?
| | Metabolome | 5 | 2019 | 350 | 0.580 |
Why?
| | Ischemic Preconditioning | 2 | 2009 | 41 | 0.550 |
Why?
| | Nanoparticles | 5 | 2024 | 481 | 0.530 |
Why?
| | Mice | 49 | 2025 | 17787 | 0.520 |
Why?
| | Fusion Proteins, bcr-abl | 5 | 2015 | 69 | 0.500 |
Why?
| | Phospholipids | 7 | 2010 | 223 | 0.500 |
Why?
| | Hypoxia | 6 | 2015 | 1112 | 0.480 |
Why?
| | Everolimus | 12 | 2013 | 91 | 0.480 |
Why?
| | Aging | 5 | 2020 | 1864 | 0.470 |
Why?
| | Rats, Wistar | 11 | 2010 | 455 | 0.470 |
Why?
| | Body Fluids | 5 | 2019 | 66 | 0.460 |
Why?
| | Glutathione | 9 | 2023 | 356 | 0.450 |
Why?
| | Inositol | 4 | 2021 | 26 | 0.450 |
Why?
| | Glutamine | 6 | 2013 | 103 | 0.450 |
Why?
| | Epilepsy, Post-Traumatic | 1 | 2013 | 3 | 0.430 |
Why?
| | Organ Specificity | 4 | 2013 | 305 | 0.430 |
Why?
| | Nephritis | 1 | 2013 | 23 | 0.420 |
Why?
| | Brain Injuries | 3 | 2014 | 494 | 0.420 |
Why?
| | Positron-Emission Tomography | 10 | 2020 | 294 | 0.420 |
Why?
| | Apoptosis | 15 | 2024 | 2553 | 0.420 |
Why?
| | Lupus Nephritis | 2 | 2011 | 63 | 0.410 |
Why?
| | Mitochondria | 7 | 2014 | 948 | 0.400 |
Why?
| | Imatinib Mesylate | 7 | 2014 | 79 | 0.390 |
Why?
| | Glioma | 4 | 2024 | 395 | 0.390 |
Why?
| | Rhabdoid Tumor | 2 | 2025 | 99 | 0.380 |
Why?
| | Leukemia | 2 | 2018 | 240 | 0.380 |
Why?
| | Blood-Brain Barrier | 3 | 2024 | 138 | 0.380 |
Why?
| | Brain Neoplasms | 6 | 2025 | 1238 | 0.380 |
Why?
| | Gene Expression Regulation, Neoplastic | 7 | 2025 | 1396 | 0.370 |
Why?
| | Humans | 75 | 2025 | 137585 | 0.370 |
Why?
| | Metabolism | 3 | 2017 | 42 | 0.360 |
Why?
| | Infratentorial Neoplasms | 2 | 2024 | 63 | 0.360 |
Why?
| | Disease Models, Animal | 16 | 2023 | 4295 | 0.360 |
Why?
| | Placenta | 3 | 2009 | 750 | 0.360 |
Why?
| | Oxidative Stress | 5 | 2010 | 1317 | 0.350 |
Why?
| | Reactive Oxygen Species | 5 | 2013 | 622 | 0.350 |
Why?
| | Drug Monitoring | 3 | 2013 | 218 | 0.350 |
Why?
| | Time Factors | 12 | 2013 | 6828 | 0.350 |
Why?
| | Myocardium | 3 | 2013 | 1002 | 0.350 |
Why?
| | Benzamides | 6 | 2009 | 216 | 0.340 |
Why?
| | Cerebellar Neoplasms | 2 | 2023 | 152 | 0.340 |
Why?
| | Kidney | 7 | 2023 | 1468 | 0.340 |
Why?
| | Medulloblastoma | 2 | 2023 | 193 | 0.330 |
Why?
| | Kidney Diseases | 2 | 2020 | 408 | 0.330 |
Why?
| | Seizures | 1 | 2013 | 426 | 0.330 |
Why?
| | Astrocytes | 4 | 2015 | 210 | 0.330 |
Why?
| | Ependymoma | 2 | 2024 | 165 | 0.330 |
Why?
| | Liver Diseases | 2 | 2010 | 315 | 0.320 |
Why?
| | Diagnostic Imaging | 2 | 2011 | 332 | 0.320 |
Why?
| | Xenograft Model Antitumor Assays | 10 | 2024 | 872 | 0.320 |
Why?
| | Molecular Probes | 1 | 2009 | 36 | 0.310 |
Why?
| | Molecular Targeted Therapy | 2 | 2017 | 411 | 0.310 |
Why?
| | Cell Proliferation | 13 | 2022 | 2475 | 0.310 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 4 | 2017 | 278 | 0.310 |
Why?
| | Glucose Transporter Type 1 | 1 | 2009 | 50 | 0.300 |
Why?
| | Silymarin | 4 | 2016 | 199 | 0.300 |
Why?
| | Lactic Acid | 7 | 2013 | 305 | 0.300 |
Why?
| | Liver Transplantation | 2 | 2007 | 871 | 0.300 |
Why?
| | Complement C3b | 2 | 2023 | 34 | 0.290 |
Why?
| | Prostatic Neoplasms | 5 | 2016 | 1043 | 0.290 |
Why?
| | Spermine | 1 | 2008 | 27 | 0.290 |
Why?
| | K562 Cells | 4 | 2009 | 89 | 0.290 |
Why?
| | Citric Acid | 1 | 2008 | 33 | 0.290 |
Why?
| | Adenosine Triphosphate | 6 | 2009 | 491 | 0.280 |
Why?
| | Hibernation | 2 | 2014 | 75 | 0.280 |
Why?
| | Adaptation, Physiological | 2 | 2009 | 553 | 0.280 |
Why?
| | Drug Design | 2 | 2007 | 167 | 0.280 |
Why?
| | Graft Rejection | 5 | 2010 | 624 | 0.270 |
Why?
| | Tomography, X-Ray Computed | 3 | 2020 | 2691 | 0.270 |
Why?
| | Kidney Transplantation | 4 | 2010 | 708 | 0.260 |
Why?
| | Creatine | 3 | 2021 | 57 | 0.260 |
Why?
| | Prostate | 1 | 2008 | 175 | 0.260 |
Why?
| | Head and Neck Neoplasms | 3 | 2019 | 606 | 0.260 |
Why?
| | Choline | 2 | 2009 | 127 | 0.260 |
Why?
| | Altitude | 3 | 2009 | 488 | 0.250 |
Why?
| | Rats, Sprague-Dawley | 11 | 2015 | 2486 | 0.250 |
Why?
| | Liver Failure | 1 | 2007 | 94 | 0.250 |
Why?
| | Male | 47 | 2024 | 67762 | 0.250 |
Why?
| | Drug Therapy | 1 | 2006 | 85 | 0.250 |
Why?
| | Pneumonia | 2 | 2011 | 639 | 0.250 |
Why?
| | Interleukin-1beta | 1 | 2008 | 372 | 0.250 |
Why?
| | Dietary Supplements | 3 | 2023 | 561 | 0.240 |
Why?
| | Colorectal Neoplasms | 4 | 2018 | 806 | 0.240 |
Why?
| | Signal Transduction | 11 | 2019 | 5079 | 0.240 |
Why?
| | Nanomedicine | 2 | 2024 | 47 | 0.240 |
Why?
| | Myocardial Reperfusion Injury | 2 | 2003 | 135 | 0.240 |
Why?
| | Brain Injuries, Traumatic | 2 | 2023 | 360 | 0.240 |
Why?
| | Blotting, Western | 6 | 2019 | 1226 | 0.240 |
Why?
| | fms-Like Tyrosine Kinase 3 | 2 | 2016 | 48 | 0.240 |
Why?
| | Sex Characteristics | 1 | 2010 | 762 | 0.240 |
Why?
| | Neovascularization, Pathologic | 4 | 2018 | 301 | 0.230 |
Why?
| | Sirtuin 2 | 1 | 2025 | 24 | 0.230 |
Why?
| | SMARCB1 Protein | 1 | 2025 | 31 | 0.230 |
Why?
| | Macrolides | 2 | 2013 | 65 | 0.230 |
Why?
| | Protein Kinases | 2 | 2004 | 319 | 0.230 |
Why?
| | Drug Interactions | 6 | 2012 | 410 | 0.220 |
Why?
| | Protein-Tyrosine Kinases | 3 | 2014 | 434 | 0.220 |
Why?
| | Positive Transcriptional Elongation Factor B | 1 | 2024 | 29 | 0.220 |
Why?
| | Microbubbles | 1 | 2024 | 49 | 0.220 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2022 | 528 | 0.220 |
Why?
| | Neurotoxicity Syndromes | 1 | 2004 | 25 | 0.220 |
Why?
| | Sepsis | 4 | 2013 | 617 | 0.220 |
Why?
| | Cell Transformation, Neoplastic | 3 | 2015 | 327 | 0.210 |
Why?
| | Dose-Response Relationship, Drug | 10 | 2012 | 2057 | 0.210 |
Why?
| | Obesity | 3 | 2006 | 2992 | 0.210 |
Why?
| | Chromatography, High Pressure Liquid | 5 | 2009 | 597 | 0.210 |
Why?
| | Organ Transplantation | 2 | 2004 | 250 | 0.210 |
Why?
| | Glycolysis | 4 | 2010 | 321 | 0.210 |
Why?
| | Autolysis | 1 | 2003 | 3 | 0.200 |
Why?
| | Autophagy | 2 | 2018 | 284 | 0.200 |
Why?
| | DNA Repair | 2 | 2024 | 231 | 0.200 |
Why?
| | Carcinoma, Hepatocellular | 2 | 2020 | 362 | 0.200 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2008 | 1242 | 0.200 |
Why?
| | Lung Transplantation | 3 | 2000 | 313 | 0.200 |
Why?
| | Fatty Liver | 1 | 2005 | 243 | 0.200 |
Why?
| | Glomerulonephritis | 1 | 2023 | 47 | 0.200 |
Why?
| | Deoxycytidine | 2 | 2017 | 179 | 0.190 |
Why?
| | Phosphates | 2 | 2001 | 182 | 0.190 |
Why?
| | In Vitro Techniques | 5 | 2016 | 1092 | 0.190 |
Why?
| | Colonic Neoplasms | 3 | 2013 | 258 | 0.180 |
Why?
| | Antineoplastic Agents, Phytogenic | 2 | 2013 | 191 | 0.180 |
Why?
| | Proto-Oncogene Proteins c-mdm2 | 1 | 2022 | 65 | 0.180 |
Why?
| | Carbon Isotopes | 3 | 2009 | 144 | 0.180 |
Why?
| | Specimen Handling | 1 | 2003 | 183 | 0.180 |
Why?
| | Mice, Nude | 8 | 2016 | 698 | 0.180 |
Why?
| | Radiation Tolerance | 1 | 2022 | 96 | 0.180 |
Why?
| | Image Processing, Computer-Assisted | 3 | 2019 | 752 | 0.180 |
Why?
| | Chemoradiotherapy | 2 | 2019 | 225 | 0.180 |
Why?
| | Hydroxamic Acids | 2 | 2011 | 89 | 0.180 |
Why?
| | Photoacoustic Techniques | 1 | 2020 | 6 | 0.180 |
Why?
| | Tendinopathy | 1 | 2021 | 27 | 0.170 |
Why?
| | Gene Expression Regulation | 4 | 2019 | 2607 | 0.170 |
Why?
| | Magnetite Nanoparticles | 2 | 2011 | 30 | 0.170 |
Why?
| | Lung | 8 | 2018 | 4060 | 0.170 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 1 | 2020 | 80 | 0.170 |
Why?
| | Anticarcinogenic Agents | 2 | 2011 | 77 | 0.170 |
Why?
| | Polycomb Repressive Complex 1 | 1 | 2020 | 50 | 0.170 |
Why?
| | Heat-Shock Proteins | 3 | 2006 | 143 | 0.170 |
Why?
| | Anterior Cruciate Ligament Injuries | 1 | 2022 | 159 | 0.170 |
Why?
| | Mass Spectrometry | 4 | 2011 | 739 | 0.160 |
Why?
| | Insulin Resistance | 2 | 2019 | 1208 | 0.160 |
Why?
| | Osteoarthritis | 1 | 2022 | 185 | 0.160 |
Why?
| | TOR Serine-Threonine Kinases | 5 | 2018 | 412 | 0.160 |
Why?
| | Mammary Glands, Animal | 2 | 2014 | 129 | 0.160 |
Why?
| | Camptothecin | 2 | 2013 | 116 | 0.160 |
Why?
| | Particle Accelerators | 1 | 2019 | 9 | 0.160 |
Why?
| | Transcriptional Elongation Factors | 1 | 2020 | 40 | 0.160 |
Why?
| | Electromagnetic Phenomena | 1 | 2019 | 22 | 0.160 |
Why?
| | Scavenger Receptors, Class A | 1 | 2019 | 12 | 0.160 |
Why?
| | Histone Deacetylase Inhibitors | 2 | 2011 | 210 | 0.160 |
Why?
| | Heart | 1 | 2003 | 655 | 0.160 |
Why?
| | Chromosomes, Human, Pair 1 | 1 | 2019 | 71 | 0.160 |
Why?
| | Brain Chemistry | 1 | 2000 | 117 | 0.160 |
Why?
| | Perfusion | 3 | 2009 | 213 | 0.160 |
Why?
| | Lactation | 2 | 2014 | 181 | 0.160 |
Why?
| | Complement Factor H | 1 | 2020 | 80 | 0.160 |
Why?
| | Macrophages, Peritoneal | 1 | 2019 | 94 | 0.160 |
Why?
| | Inflammation | 4 | 2024 | 2837 | 0.160 |
Why?
| | Endoplasmic Reticulum Stress | 3 | 2014 | 110 | 0.160 |
Why?
| | Fatty Acids | 2 | 2015 | 443 | 0.160 |
Why?
| | Fluorodeoxyglucose F18 | 2 | 2021 | 135 | 0.150 |
Why?
| | Precursor Cells, B-Lymphoid | 2 | 2017 | 40 | 0.150 |
Why?
| | Proto-Oncogene Proteins c-myc | 2 | 2021 | 139 | 0.150 |
Why?
| | Receptor, EphB4 | 1 | 2019 | 34 | 0.150 |
Why?
| | Ephrin-B2 | 1 | 2019 | 47 | 0.150 |
Why?
| | Lipogenesis | 2 | 2016 | 61 | 0.150 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 5 | 2014 | 1692 | 0.150 |
Why?
| | Angiogenesis Inhibitors | 2 | 2011 | 229 | 0.150 |
Why?
| | Whey Proteins | 1 | 2018 | 6 | 0.150 |
Why?
| | Neoplasm Proteins | 2 | 2020 | 434 | 0.150 |
Why?
| | Smad4 Protein | 1 | 2018 | 38 | 0.150 |
Why?
| | Glucose Clamp Technique | 1 | 2019 | 195 | 0.150 |
Why?
| | Phosphocreatine | 3 | 2004 | 46 | 0.140 |
Why?
| | Salivary Gland Neoplasms | 1 | 2018 | 41 | 0.140 |
Why?
| | Anilides | 1 | 2018 | 73 | 0.140 |
Why?
| | Tumor Microenvironment | 2 | 2019 | 674 | 0.140 |
Why?
| | Polyenes | 1 | 1997 | 16 | 0.140 |
Why?
| | Histones | 2 | 2020 | 636 | 0.140 |
Why?
| | Tracheal Stenosis | 1 | 2018 | 31 | 0.140 |
Why?
| | Acute Lung Injury | 2 | 2011 | 287 | 0.140 |
Why?
| | Rats, Zucker | 3 | 2006 | 35 | 0.140 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 3 | 2013 | 267 | 0.140 |
Why?
| | Mucin-1 | 1 | 2017 | 21 | 0.140 |
Why?
| | Cells, Cultured | 6 | 2019 | 4193 | 0.140 |
Why?
| | Kinetics | 3 | 2009 | 1670 | 0.140 |
Why?
| | Folic Acid Deficiency | 1 | 2017 | 49 | 0.140 |
Why?
| | Neuroprotective Agents | 1 | 2018 | 131 | 0.130 |
Why?
| | Phosphorylation | 4 | 2013 | 1759 | 0.130 |
Why?
| | Fibroblasts | 2 | 2016 | 996 | 0.130 |
Why?
| | Lactates | 3 | 2006 | 85 | 0.130 |
Why?
| | PTEN Phosphohydrolase | 1 | 2018 | 167 | 0.130 |
Why?
| | Drug Synergism | 5 | 2013 | 382 | 0.130 |
Why?
| | Adenosine Diphosphate | 2 | 2009 | 79 | 0.130 |
Why?
| | Female | 28 | 2022 | 73304 | 0.130 |
Why?
| | Quinazolines | 2 | 2008 | 251 | 0.130 |
Why?
| | Macrophages | 3 | 2019 | 1547 | 0.130 |
Why?
| | Ataxia Telangiectasia Mutated Proteins | 1 | 2016 | 66 | 0.130 |
Why?
| | Tissue Extracts | 2 | 2009 | 21 | 0.130 |
Why?
| | Inflammation Mediators | 1 | 2019 | 513 | 0.130 |
Why?
| | Gene Expression Regulation, Leukemic | 1 | 2016 | 56 | 0.130 |
Why?
| | Heme Oxygenase (Decyclizing) | 2 | 2013 | 22 | 0.130 |
Why?
| | Pancreatic Neoplasms | 2 | 2017 | 938 | 0.130 |
Why?
| | Hematopoiesis | 1 | 2017 | 192 | 0.130 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 3 | 2013 | 86 | 0.130 |
Why?
| | Glucosephosphate Dehydrogenase | 1 | 2016 | 60 | 0.130 |
Why?
| | Folic Acid | 1 | 2017 | 186 | 0.130 |
Why?
| | Alcohol Oxidoreductases | 1 | 2016 | 62 | 0.120 |
Why?
| | Transcription Factors | 5 | 2014 | 1719 | 0.120 |
Why?
| | Blood Glucose | 4 | 2019 | 2186 | 0.120 |
Why?
| | Creatinine | 4 | 2005 | 499 | 0.120 |
Why?
| | Pyrazoles | 2 | 2010 | 423 | 0.120 |
Why?
| | Lipid Peroxidation | 3 | 2006 | 153 | 0.120 |
Why?
| | Liver Neoplasms | 2 | 2020 | 786 | 0.120 |
Why?
| | Flow Cytometry | 2 | 2010 | 1178 | 0.120 |
Why?
| | Familial Primary Pulmonary Hypertension | 1 | 2016 | 198 | 0.120 |
Why?
| | Fluorouracil | 2 | 2024 | 208 | 0.120 |
Why?
| | Drug Delivery Systems | 3 | 2024 | 365 | 0.120 |
Why?
| | Neuroglia | 1 | 1996 | 173 | 0.120 |
Why?
| | Radiography | 2 | 2008 | 822 | 0.120 |
Why?
| | Hypothermia, Induced | 2 | 2006 | 80 | 0.120 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 4 | 2011 | 340 | 0.120 |
Why?
| | Hernias, Diaphragmatic, Congenital | 1 | 2018 | 201 | 0.120 |
Why?
| | Lipid Metabolism | 4 | 2019 | 518 | 0.120 |
Why?
| | Brain Concussion | 1 | 2023 | 574 | 0.120 |
Why?
| | Methylamines | 2 | 2005 | 34 | 0.120 |
Why?
| | Paracrine Communication | 1 | 2015 | 65 | 0.120 |
Why?
| | Oligomycins | 1 | 2014 | 7 | 0.120 |
Why?
| | Myocardial Infarction | 1 | 2002 | 1046 | 0.120 |
Why?
| | Mitochondrial Proton-Translocating ATPases | 1 | 2014 | 19 | 0.110 |
Why?
| | Proto-Oncogene Proteins c-akt | 3 | 2018 | 437 | 0.110 |
Why?
| | Nuclear Proteins | 2 | 2023 | 712 | 0.110 |
Why?
| | Fatty Acids, Unsaturated | 2 | 2005 | 99 | 0.110 |
Why?
| | Pentacyclic Triterpenes | 1 | 2014 | 15 | 0.110 |
Why?
| | Homeostasis | 1 | 2018 | 621 | 0.110 |
Why?
| | Pyridines | 1 | 2018 | 506 | 0.110 |
Why?
| | Models, Animal | 2 | 2009 | 384 | 0.110 |
Why?
| | Ferric Compounds | 1 | 2014 | 56 | 0.110 |
Why?
| | Fatty Acid Synthase, Type I | 1 | 2014 | 11 | 0.110 |
Why?
| | Hypertension, Pulmonary | 2 | 2016 | 1910 | 0.110 |
Why?
| | ras Proteins | 2 | 2013 | 153 | 0.110 |
Why?
| | Rats, Inbred Lew | 4 | 2010 | 114 | 0.110 |
Why?
| | Indoles | 2 | 2015 | 412 | 0.110 |
Why?
| | Lipoxygenase Inhibitors | 1 | 2014 | 37 | 0.110 |
Why?
| | Leukotrienes | 1 | 2014 | 37 | 0.110 |
Why?
| | Convulsants | 1 | 2013 | 8 | 0.110 |
Why?
| | Treatment Outcome | 9 | 2024 | 10811 | 0.110 |
Why?
| | Dextrans | 2 | 2014 | 84 | 0.110 |
Why?
| | Kainic Acid | 1 | 2013 | 35 | 0.110 |
Why?
| | NAD | 2 | 2004 | 77 | 0.100 |
Why?
| | Propranolol | 1 | 2013 | 50 | 0.100 |
Why?
| | Urothelium | 1 | 2013 | 37 | 0.100 |
Why?
| | Brain Edema | 1 | 2013 | 61 | 0.100 |
Why?
| | Azoxymethane | 1 | 2013 | 20 | 0.100 |
Why?
| | Unfolded Protein Response | 1 | 2013 | 59 | 0.100 |
Why?
| | Mice, Inbred BALB C | 4 | 2019 | 1272 | 0.100 |
Why?
| | Prognosis | 4 | 2017 | 4030 | 0.100 |
Why?
| | Cell Survival | 4 | 2016 | 1120 | 0.100 |
Why?
| | Fetal Growth Retardation | 1 | 2019 | 565 | 0.100 |
Why?
| | Grape Seed Extract | 1 | 2013 | 44 | 0.100 |
Why?
| | Equipment Design | 2 | 2019 | 522 | 0.100 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2019 | 976 | 0.100 |
Why?
| | Triple Negative Breast Neoplasms | 1 | 2015 | 202 | 0.100 |
Why?
| | Phytic Acid | 1 | 2012 | 42 | 0.100 |
Why?
| | Tumor Cells, Cultured | 3 | 2019 | 955 | 0.100 |
Why?
| | Estrogens | 1 | 2015 | 367 | 0.100 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 2 | 2015 | 108 | 0.100 |
Why?
| | Severity of Illness Index | 2 | 2013 | 2828 | 0.100 |
Why?
| | Shock, Hemorrhagic | 1 | 2014 | 167 | 0.100 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2013 | 153 | 0.100 |
Why?
| | Metabolic Diseases | 1 | 2013 | 108 | 0.100 |
Why?
| | Thiophenes | 1 | 2013 | 117 | 0.100 |
Why?
| | Pregnancy | 6 | 2019 | 6763 | 0.090 |
Why?
| | Insulin | 3 | 2019 | 2409 | 0.090 |
Why?
| | Image Enhancement | 2 | 2010 | 190 | 0.090 |
Why?
| | Reference Values | 3 | 2019 | 816 | 0.090 |
Why?
| | DNA-Binding Proteins | 3 | 2016 | 1502 | 0.090 |
Why?
| | Radionuclide Imaging | 1 | 2012 | 118 | 0.090 |
Why?
| | Mice, Transgenic | 6 | 2015 | 2167 | 0.090 |
Why?
| | Quinolines | 1 | 2013 | 178 | 0.090 |
Why?
| | Proto-Oncogene Proteins | 2 | 2013 | 648 | 0.090 |
Why?
| | HSP70 Heat-Shock Proteins | 3 | 2010 | 73 | 0.090 |
Why?
| | Feasibility Studies | 2 | 2019 | 956 | 0.090 |
Why?
| | Isotope Labeling | 1 | 2012 | 81 | 0.090 |
Why?
| | Temperature | 3 | 2014 | 679 | 0.090 |
Why?
| | Calcineurin | 1 | 2012 | 108 | 0.090 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2013 | 323 | 0.090 |
Why?
| | Urinary Bladder | 1 | 2013 | 183 | 0.090 |
Why?
| | Tissue Distribution | 2 | 2003 | 332 | 0.090 |
Why?
| | Mice, Inbred NOD | 3 | 2019 | 601 | 0.090 |
Why?
| | Reproducibility of Results | 5 | 2019 | 3284 | 0.090 |
Why?
| | Proteasome Inhibitors | 1 | 2011 | 46 | 0.090 |
Why?
| | Sarcoma | 1 | 2013 | 188 | 0.090 |
Why?
| | Boronic Acids | 1 | 2011 | 37 | 0.090 |
Why?
| | Electroencephalography | 1 | 2013 | 423 | 0.090 |
Why?
| | Glioblastoma | 1 | 2014 | 345 | 0.090 |
Why?
| | Models, Biological | 5 | 2013 | 1783 | 0.090 |
Why?
| | Tandem Mass Spectrometry | 2 | 2014 | 532 | 0.090 |
Why?
| | Sciuridae | 2 | 2014 | 147 | 0.090 |
Why?
| | Antibodies, Monoclonal | 3 | 2023 | 1430 | 0.090 |
Why?
| | Nucleotides | 2 | 2017 | 125 | 0.090 |
Why?
| | Tacrolimus | 1 | 2012 | 199 | 0.090 |
Why?
| | Benzimidazoles | 1 | 2011 | 170 | 0.080 |
Why?
| | Phosphatidylinositol 3-Kinases | 3 | 2018 | 366 | 0.080 |
Why?
| | Protease Inhibitors | 1 | 2011 | 107 | 0.080 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2010 | 173 | 0.080 |
Why?
| | Hydroxybutyrates | 2 | 2010 | 14 | 0.080 |
Why?
| | Complement C3-C5 Convertases | 1 | 2010 | 24 | 0.080 |
Why?
| | Pyrazines | 1 | 2011 | 90 | 0.080 |
Why?
| | Adult | 10 | 2013 | 37929 | 0.080 |
Why?
| | Heart Ventricles | 1 | 2015 | 788 | 0.080 |
Why?
| | Cricetulus | 1 | 2010 | 109 | 0.080 |
Why?
| | Cognition Disorders | 1 | 2014 | 496 | 0.080 |
Why?
| | CHO Cells | 1 | 2010 | 161 | 0.080 |
Why?
| | Cricetinae | 1 | 2010 | 289 | 0.080 |
Why?
| | Epigenomics | 2 | 2020 | 115 | 0.080 |
Why?
| | Fatty Acids, Monounsaturated | 2 | 2010 | 54 | 0.080 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2016 | 630 | 0.080 |
Why?
| | TRPP Cation Channels | 1 | 2010 | 85 | 0.080 |
Why?
| | Analysis of Variance | 2 | 2010 | 1316 | 0.080 |
Why?
| | ErbB Receptors | 2 | 2015 | 614 | 0.080 |
Why?
| | Neoplasm Transplantation | 3 | 2019 | 257 | 0.080 |
Why?
| | Ribose | 1 | 2009 | 23 | 0.080 |
Why?
| | Mice, Knockout | 5 | 2020 | 3015 | 0.080 |
Why?
| | Cysts | 1 | 2010 | 113 | 0.080 |
Why?
| | Dinoprost | 1 | 2009 | 44 | 0.080 |
Why?
| | Cell Extracts | 1 | 2009 | 21 | 0.080 |
Why?
| | Deoxyglucose | 1 | 2009 | 53 | 0.080 |
Why?
| | RNA, Neoplasm | 1 | 2009 | 82 | 0.080 |
Why?
| | Intestine, Small | 1 | 2010 | 156 | 0.080 |
Why?
| | Percussion | 1 | 2008 | 2 | 0.080 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2009 | 132 | 0.080 |
Why?
| | Surgical Equipment | 1 | 2008 | 11 | 0.080 |
Why?
| | History, 21st Century | 1 | 2009 | 213 | 0.070 |
Why?
| | Sulfonamides | 2 | 2011 | 513 | 0.070 |
Why?
| | Alanine | 2 | 2013 | 152 | 0.070 |
Why?
| | Receptor, ErbB-3 | 1 | 2008 | 44 | 0.070 |
Why?
| | Macaca fascicularis | 4 | 2000 | 65 | 0.070 |
Why?
| | Mutation | 3 | 2020 | 3958 | 0.070 |
Why?
| | History, 20th Century | 1 | 2009 | 325 | 0.070 |
Why?
| | Systems Biology | 1 | 2009 | 67 | 0.070 |
Why?
| | Complement C3d | 2 | 2023 | 67 | 0.070 |
Why?
| | Oxygen | 2 | 2010 | 931 | 0.070 |
Why?
| | Body Weight | 4 | 2012 | 985 | 0.070 |
Why?
| | Oxidation-Reduction | 3 | 2016 | 1060 | 0.070 |
Why?
| | Neurons | 1 | 1996 | 1590 | 0.070 |
Why?
| | Area Under Curve | 1 | 2008 | 314 | 0.070 |
Why?
| | Protein Transport | 1 | 2009 | 445 | 0.070 |
Why?
| | Critical Illness | 2 | 2011 | 811 | 0.070 |
Why?
| | Triglycerides | 2 | 2010 | 524 | 0.070 |
Why?
| | DNA | 2 | 2009 | 1459 | 0.070 |
Why?
| | Lymphocytes | 1 | 2009 | 397 | 0.070 |
Why?
| | Disease Progression | 5 | 2018 | 2757 | 0.070 |
Why?
| | Heart-Assist Devices | 1 | 2013 | 552 | 0.070 |
Why?
| | Heterografts | 2 | 2019 | 138 | 0.070 |
Why?
| | Oxidative Phosphorylation | 2 | 2005 | 193 | 0.070 |
Why?
| | X-Ray Microtomography | 2 | 2021 | 94 | 0.070 |
Why?
| | Tritium | 1 | 2006 | 76 | 0.070 |
Why?
| | Up-Regulation | 2 | 2006 | 843 | 0.060 |
Why?
| | Age Factors | 2 | 2011 | 3295 | 0.060 |
Why?
| | MicroRNAs | 1 | 2013 | 692 | 0.060 |
Why?
| | Medical Oncology | 1 | 2009 | 289 | 0.060 |
Why?
| | ROC Curve | 1 | 2008 | 554 | 0.060 |
Why?
| | Chromatin | 2 | 2020 | 519 | 0.060 |
Why?
| | Body Temperature | 1 | 2007 | 222 | 0.060 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 1 | 2010 | 262 | 0.060 |
Why?
| | Mice, Inbred C57BL | 5 | 2018 | 5757 | 0.060 |
Why?
| | Leukocytes, Mononuclear | 1 | 2009 | 558 | 0.060 |
Why?
| | Maximum Tolerated Dose | 3 | 2013 | 199 | 0.060 |
Why?
| | Nitrogen | 1 | 2007 | 168 | 0.060 |
Why?
| | Receptor, ErbB-2 | 1 | 2008 | 341 | 0.060 |
Why?
| | Piperidines | 1 | 2007 | 206 | 0.060 |
Why?
| | Heat-Shock Response | 1 | 2006 | 77 | 0.060 |
Why?
| | Liver Failure, Acute | 1 | 2006 | 67 | 0.060 |
Why?
| | Allantoin | 1 | 2005 | 2 | 0.060 |
Why?
| | Survival Rate | 3 | 2019 | 1972 | 0.060 |
Why?
| | Cell Differentiation | 2 | 2025 | 1991 | 0.060 |
Why?
| | Betaine | 1 | 2005 | 73 | 0.060 |
Why?
| | Lung Injury | 1 | 2008 | 219 | 0.060 |
Why?
| | Deuterium | 1 | 2005 | 99 | 0.060 |
Why?
| | Alcohol Drinking | 1 | 2012 | 828 | 0.060 |
Why?
| | Glutamic Acid | 2 | 2010 | 246 | 0.060 |
Why?
| | Methionine | 1 | 2005 | 160 | 0.060 |
Why?
| | Glutamates | 1 | 2004 | 59 | 0.060 |
Why?
| | Reference Standards | 2 | 2019 | 186 | 0.060 |
Why?
| | Seasons | 1 | 2007 | 547 | 0.060 |
Why?
| | Mitochondrial Encephalomyopathies | 1 | 2004 | 9 | 0.060 |
Why?
| | Heart Rate | 2 | 2009 | 822 | 0.050 |
Why?
| | Free Radical Scavengers | 1 | 2004 | 88 | 0.050 |
Why?
| | Dacarbazine | 2 | 2014 | 98 | 0.050 |
Why?
| | Biological Transport | 2 | 2015 | 418 | 0.050 |
Why?
| | Uric Acid | 1 | 2005 | 163 | 0.050 |
Why?
| | HSP72 Heat-Shock Proteins | 1 | 2003 | 32 | 0.050 |
Why?
| | Chromosomes | 1 | 2024 | 107 | 0.050 |
Why?
| | Hypoxia-Ischemia, Brain | 1 | 2004 | 37 | 0.050 |
Why?
| | Cholesterol | 1 | 2005 | 410 | 0.050 |
Why?
| | Lipids | 2 | 2021 | 672 | 0.050 |
Why?
| | Gene Expression Profiling | 3 | 2019 | 1774 | 0.050 |
Why?
| | Hot Temperature | 1 | 2006 | 391 | 0.050 |
Why?
| | Calcineurin Inhibitors | 1 | 2003 | 72 | 0.050 |
Why?
| | Proteins | 1 | 2009 | 1009 | 0.050 |
Why?
| | Injections, Intravenous | 1 | 2003 | 206 | 0.050 |
Why?
| | Transcription, Genetic | 2 | 2024 | 1457 | 0.050 |
Why?
| | RNA, Small Interfering | 2 | 2016 | 622 | 0.050 |
Why?
| | Aged | 5 | 2013 | 23961 | 0.050 |
Why?
| | Cardiac Output | 1 | 2003 | 165 | 0.050 |
Why?
| | Wounds and Injuries | 1 | 2010 | 758 | 0.050 |
Why?
| | Gliosis | 1 | 2023 | 28 | 0.050 |
Why?
| | Acetylcysteine | 1 | 2004 | 145 | 0.050 |
Why?
| | Drug Carriers | 1 | 2024 | 128 | 0.050 |
Why?
| | Coronary Circulation | 1 | 2003 | 143 | 0.050 |
Why?
| | Mitochondria, Liver | 1 | 2003 | 73 | 0.050 |
Why?
| | Tyrosine | 1 | 2023 | 222 | 0.050 |
Why?
| | Necrosis | 3 | 2010 | 246 | 0.050 |
Why?
| | Mitochondria, Heart | 1 | 2003 | 102 | 0.050 |
Why?
| | Anesthetics, Intravenous | 1 | 2002 | 47 | 0.050 |
Why?
| | Isoflurane | 1 | 2002 | 31 | 0.050 |
Why?
| | Protein Tyrosine Phosphatases | 1 | 2023 | 172 | 0.050 |
Why?
| | Models, Cardiovascular | 1 | 2003 | 198 | 0.050 |
Why?
| | Liposomes | 1 | 2024 | 223 | 0.050 |
Why?
| | Rupture | 1 | 2022 | 92 | 0.050 |
Why?
| | Child | 4 | 2024 | 21935 | 0.050 |
Why?
| | Reperfusion | 1 | 2002 | 40 | 0.050 |
Why?
| | Anterior Cruciate Ligament | 1 | 2022 | 81 | 0.050 |
Why?
| | Adenocarcinoma | 1 | 2009 | 940 | 0.050 |
Why?
| | Oxaloacetic Acid | 1 | 2001 | 4 | 0.050 |
Why?
| | Tumor Burden | 2 | 2014 | 309 | 0.050 |
Why?
| | Succinic Acid | 2 | 2013 | 37 | 0.040 |
Why?
| | AMP-Activated Protein Kinases | 2 | 2013 | 197 | 0.040 |
Why?
| | Aspartic Acid | 1 | 2001 | 79 | 0.040 |
Why?
| | Tibia | 1 | 2022 | 178 | 0.040 |
Why?
| | RNA Polymerase II | 1 | 2024 | 324 | 0.040 |
Why?
| | Microsomes, Liver | 1 | 2001 | 86 | 0.040 |
Why?
| | Teratoma | 1 | 2022 | 114 | 0.040 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2021 | 98 | 0.040 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2023 | 455 | 0.040 |
Why?
| | Random Allocation | 3 | 2006 | 353 | 0.040 |
Why?
| | Middle Aged | 6 | 2016 | 33479 | 0.040 |
Why?
| | Drug Therapy, Combination | 3 | 2016 | 1066 | 0.040 |
Why?
| | Coronary Vessels | 1 | 2002 | 248 | 0.040 |
Why?
| | Brain Stem Neoplasms | 1 | 2020 | 83 | 0.040 |
Why?
| | Pulmonary Alveoli | 1 | 2002 | 405 | 0.040 |
Why?
| | Hematinics | 1 | 2019 | 22 | 0.040 |
Why?
| | Tunica Intima | 1 | 2000 | 84 | 0.040 |
Why?
| | Ligands | 2 | 2012 | 664 | 0.040 |
Why?
| | Astrocytoma | 1 | 2020 | 128 | 0.040 |
Why?
| | gamma-Aminobutyric Acid | 1 | 2001 | 198 | 0.040 |
Why?
| | Heart Failure | 1 | 2013 | 2236 | 0.040 |
Why?
| | Phenotype | 3 | 2016 | 3196 | 0.040 |
Why?
| | Cell Movement | 2 | 2015 | 967 | 0.040 |
Why?
| | Sheep, Domestic | 1 | 2019 | 34 | 0.040 |
Why?
| | Enzyme Activation | 2 | 2013 | 810 | 0.040 |
Why?
| | Pregnancy Complications | 1 | 2004 | 527 | 0.040 |
Why?
| | Fluorescent Antibody Technique | 2 | 2013 | 390 | 0.040 |
Why?
| | Mice, SCID | 1 | 2019 | 367 | 0.040 |
Why?
| | Mouth Mucosa | 1 | 2019 | 92 | 0.040 |
Why?
| | Radiology, Interventional | 1 | 2019 | 33 | 0.040 |
Why?
| | Drug Administration Schedule | 2 | 2013 | 786 | 0.040 |
Why?
| | Survival Analysis | 2 | 2016 | 1325 | 0.040 |
Why?
| | Knee Joint | 1 | 2022 | 409 | 0.040 |
Why?
| | Chromatography, Liquid | 1 | 2000 | 433 | 0.040 |
Why?
| | Transplantation, Homologous | 1 | 2000 | 416 | 0.040 |
Why?
| | Mifepristone | 1 | 2018 | 64 | 0.040 |
Why?
| | Carcinoma, Adenoid Cystic | 1 | 2018 | 17 | 0.040 |
Why?
| | Salivary Glands | 1 | 2018 | 33 | 0.040 |
Why?
| | Lysine | 1 | 2020 | 294 | 0.040 |
Why?
| | Anthropometry | 1 | 2019 | 213 | 0.040 |
Why?
| | Amino Acids | 1 | 2002 | 497 | 0.040 |
Why?
| | Breast | 1 | 2019 | 151 | 0.040 |
Why?
| | NF-kappa B | 2 | 2013 | 691 | 0.040 |
Why?
| | Phantoms, Imaging | 1 | 2019 | 152 | 0.040 |
Why?
| | Citric Acid Cycle | 1 | 1997 | 57 | 0.040 |
Why?
| | Cell Size | 1 | 1997 | 91 | 0.030 |
Why?
| | Immunohistochemistry | 2 | 2012 | 1738 | 0.030 |
Why?
| | Robotics | 1 | 2019 | 94 | 0.030 |
Why?
| | Weight Gain | 1 | 2001 | 519 | 0.030 |
Why?
| | Digoxin | 1 | 2017 | 31 | 0.030 |
Why?
| | Pentose Phosphate Pathway | 1 | 2017 | 53 | 0.030 |
Why?
| | Lung Neoplasms | 1 | 2010 | 2526 | 0.030 |
Why?
| | Cytosol | 1 | 1997 | 226 | 0.030 |
Why?
| | Diet, High-Fat | 1 | 2018 | 247 | 0.030 |
Why?
| | Aorta | 1 | 2000 | 417 | 0.030 |
Why?
| | Cysteine | 1 | 2018 | 204 | 0.030 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 2 | 2010 | 71 | 0.030 |
Why?
| | Benzothiazoles | 1 | 2016 | 33 | 0.030 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2019 | 267 | 0.030 |
Why?
| | Rabbits | 1 | 2018 | 794 | 0.030 |
Why?
| | Hydrazines | 1 | 2016 | 35 | 0.030 |
Why?
| | Lymph Nodes | 1 | 2019 | 491 | 0.030 |
Why?
| | Adventitia | 1 | 2016 | 40 | 0.030 |
Why?
| | Heat Shock Transcription Factors | 2 | 2006 | 19 | 0.030 |
Why?
| | Membrane Lipids | 1 | 1996 | 91 | 0.030 |
Why?
| | Phenylurea Compounds | 1 | 2016 | 97 | 0.030 |
Why?
| | Carbon | 1 | 2017 | 216 | 0.030 |
Why?
| | Cell Hypoxia | 1 | 2016 | 226 | 0.030 |
Why?
| | Fatty Acid Transport Proteins | 1 | 2015 | 19 | 0.030 |
Why?
| | Epoxy Compounds | 1 | 2015 | 33 | 0.030 |
Why?
| | Gestational Age | 1 | 2019 | 910 | 0.030 |
Why?
| | Transforming Growth Factor beta | 1 | 2018 | 480 | 0.030 |
Why?
| | Animals, Newborn | 1 | 1997 | 844 | 0.030 |
Why?
| | Carnitine O-Palmitoyltransferase | 1 | 2015 | 46 | 0.030 |
Why?
| | Stem Cell Niche | 1 | 2015 | 54 | 0.030 |
Why?
| | Dihydrolipoyllysine-Residue Acetyltransferase | 1 | 2014 | 6 | 0.030 |
Why?
| | Ketone Oxidoreductases | 1 | 2014 | 7 | 0.030 |
Why?
| | Epigenesis, Genetic | 1 | 2020 | 660 | 0.030 |
Why?
| | Lipoprotein Lipase | 1 | 2015 | 59 | 0.030 |
Why?
| | Sodium Hydroxide | 1 | 2014 | 8 | 0.030 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2014 | 72 | 0.030 |
Why?
| | Precision Medicine | 1 | 2019 | 429 | 0.030 |
Why?
| | Risk Factors | 1 | 2009 | 10388 | 0.030 |
Why?
| | Half-Life | 1 | 2014 | 164 | 0.030 |
Why?
| | Radiopharmaceuticals | 1 | 2015 | 178 | 0.030 |
Why?
| | Gene Knockdown Techniques | 1 | 2015 | 327 | 0.030 |
Why?
| | Superoxides | 1 | 2014 | 202 | 0.030 |
Why?
| | Recovery of Function | 1 | 2018 | 653 | 0.030 |
Why?
| | Bone Marrow | 1 | 2015 | 286 | 0.030 |
Why?
| | Pyrroles | 1 | 2015 | 213 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2020 | 1079 | 0.030 |
Why?
| | Maze Learning | 1 | 2014 | 103 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2015 | 510 | 0.030 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2014 | 188 | 0.030 |
Why?
| | Mice, Mutant Strains | 1 | 2014 | 298 | 0.030 |
Why?
| | Enzyme Induction | 1 | 2013 | 90 | 0.030 |
Why?
| | Software | 1 | 2019 | 665 | 0.030 |
Why?
| | beta-Galactosidase | 1 | 2013 | 78 | 0.030 |
Why?
| | Breeding | 1 | 2013 | 64 | 0.030 |
Why?
| | Mice, Inbred A | 1 | 2013 | 49 | 0.030 |
Why?
| | Amino Acids, Aromatic | 1 | 2013 | 7 | 0.030 |
Why?
| | Antineoplastic Agents, Alkylating | 1 | 2013 | 73 | 0.030 |
Why?
| | Particle Size | 1 | 2014 | 394 | 0.030 |
Why?
| | Catalysis | 1 | 2014 | 307 | 0.030 |
Why?
| | Somatomedins | 1 | 2013 | 27 | 0.030 |
Why?
| | Staining and Labeling | 1 | 2013 | 150 | 0.030 |
Why?
| | Vacuoles | 1 | 2013 | 40 | 0.030 |
Why?
| | Cell Shape | 1 | 2013 | 57 | 0.030 |
Why?
| | Mitogens | 1 | 2013 | 61 | 0.030 |
Why?
| | Hyperplasia | 1 | 2013 | 175 | 0.030 |
Why?
| | Tissue Donors | 2 | 2010 | 425 | 0.030 |
Why?
| | Keratins | 1 | 2013 | 173 | 0.030 |
Why?
| | RNA Interference | 1 | 2014 | 469 | 0.020 |
Why?
| | Risk Assessment | 1 | 2002 | 3457 | 0.020 |
Why?
| | Immunoenzyme Techniques | 1 | 2013 | 219 | 0.020 |
Why?
| | Glucose Transporter Type 4 | 1 | 2012 | 40 | 0.020 |
Why?
| | Adenoviridae | 1 | 2013 | 193 | 0.020 |
Why?
| | Integrases | 1 | 2013 | 120 | 0.020 |
Why?
| | Transplantation, Heterologous | 1 | 2013 | 194 | 0.020 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2013 | 95 | 0.020 |
Why?
| | Transcriptome | 1 | 2019 | 971 | 0.020 |
Why?
| | Carcinogens | 1 | 2013 | 125 | 0.020 |
Why?
| | Epidermal Growth Factor | 1 | 2013 | 177 | 0.020 |
Why?
| | Mitochondrial Proteins | 1 | 2014 | 257 | 0.020 |
Why?
| | RNA, Messenger | 2 | 2013 | 2833 | 0.020 |
Why?
| | Neoplasm Grading | 1 | 2013 | 307 | 0.020 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2013 | 171 | 0.020 |
Why?
| | RNA, Untranslated | 1 | 2013 | 124 | 0.020 |
Why?
| | Long-Term Potentiation | 1 | 2014 | 198 | 0.020 |
Why?
| | Estradiol | 1 | 2015 | 521 | 0.020 |
Why?
| | Mice, Inbred MRL lpr | 1 | 2011 | 38 | 0.020 |
Why?
| | Self Administration | 1 | 2012 | 123 | 0.020 |
Why?
| | Molecular Chaperones | 1 | 2013 | 195 | 0.020 |
Why?
| | Colorado | 1 | 2022 | 4565 | 0.020 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2013 | 313 | 0.020 |
Why?
| | Decision Making | 1 | 2019 | 900 | 0.020 |
Why?
| | Sucrose | 1 | 2012 | 110 | 0.020 |
Why?
| | Bortezomib | 1 | 2011 | 54 | 0.020 |
Why?
| | Gene Regulatory Networks | 1 | 2013 | 305 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2013 | 767 | 0.020 |
Why?
| | Nestin | 1 | 2010 | 19 | 0.020 |
Why?
| | beta Catenin | 1 | 2013 | 253 | 0.020 |
Why?
| | Adenine | 1 | 2013 | 271 | 0.020 |
Why?
| | Intermediate Filament Proteins | 1 | 2010 | 57 | 0.020 |
Why?
| | Kidney Glomerulus | 1 | 2011 | 119 | 0.020 |
Why?
| | Urethane | 1 | 2010 | 43 | 0.020 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2013 | 224 | 0.020 |
Why?
| | Fatigue | 1 | 2013 | 329 | 0.020 |
Why?
| | Receptors, Complement 3d | 1 | 2011 | 141 | 0.020 |
Why?
| | Neutrophils | 2 | 2006 | 1238 | 0.020 |
Why?
| | Immunoblotting | 1 | 2011 | 308 | 0.020 |
Why?
| | Mesenteric Arteries | 1 | 2010 | 16 | 0.020 |
Why?
| | HT29 Cells | 1 | 2010 | 41 | 0.020 |
Why?
| | Cluster Analysis | 1 | 2011 | 499 | 0.020 |
Why?
| | Kidney Function Tests | 1 | 2010 | 160 | 0.020 |
Why?
| | Protein Biosynthesis | 1 | 2013 | 433 | 0.020 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2011 | 156 | 0.020 |
Why?
| | Hydrogen | 1 | 2010 | 70 | 0.020 |
Why?
| | Caspase 3 | 1 | 2011 | 246 | 0.020 |
Why?
| | Ki-67 Antigen | 1 | 2010 | 112 | 0.020 |
Why?
| | Limit of Detection | 1 | 2009 | 85 | 0.020 |
Why?
| | Capillary Permeability | 1 | 2010 | 145 | 0.020 |
Why?
| | Transplantation Conditioning | 1 | 2010 | 170 | 0.020 |
Why?
| | Constriction, Pathologic | 1 | 2010 | 245 | 0.020 |
Why?
| | Citrates | 1 | 2009 | 44 | 0.020 |
Why?
| | Gene Deletion | 1 | 2010 | 391 | 0.020 |
Why?
| | Portal Vein | 1 | 2010 | 120 | 0.020 |
Why?
| | STAT3 Transcription Factor | 1 | 2010 | 206 | 0.020 |
Why?
| | Celecoxib | 1 | 2008 | 39 | 0.020 |
Why?
| | Capecitabine | 1 | 2008 | 45 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2010 | 413 | 0.020 |
Why?
| | Aged, 80 and over | 2 | 2013 | 7635 | 0.020 |
Why?
| | Free Radicals | 1 | 2009 | 110 | 0.020 |
Why?
| | Bronchoscopy | 2 | 2000 | 223 | 0.020 |
Why?
| | Cell Cycle | 1 | 2011 | 601 | 0.020 |
Why?
| | Hippocampus | 1 | 2014 | 895 | 0.020 |
Why?
| | Mammary Tumor Virus, Mouse | 1 | 2008 | 44 | 0.020 |
Why?
| | Principal Component Analysis | 1 | 2009 | 195 | 0.020 |
Why?
| | Dura Mater | 1 | 2008 | 34 | 0.020 |
Why?
| | Mammary Neoplasms, Animal | 1 | 2008 | 33 | 0.020 |
Why?
| | Craniotomy | 1 | 2008 | 77 | 0.020 |
Why?
| | Genotype | 1 | 2013 | 1916 | 0.020 |
Why?
| | Down-Regulation | 1 | 2010 | 657 | 0.020 |
Why?
| | Drug Discovery | 1 | 2009 | 142 | 0.020 |
Why?
| | Pressure | 1 | 2008 | 225 | 0.020 |
Why?
| | Ethanol | 1 | 2012 | 608 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2010 | 545 | 0.020 |
Why?
| | Nerve Tissue Proteins | 1 | 2010 | 596 | 0.020 |
Why?
| | United States | 1 | 2024 | 14841 | 0.020 |
Why?
| | Carcinoma | 1 | 2008 | 240 | 0.020 |
Why?
| | Aspartate Aminotransferases | 1 | 2006 | 90 | 0.020 |
Why?
| | Hypoglycemic Agents | 1 | 2015 | 1291 | 0.020 |
Why?
| | Peroxidase | 1 | 2006 | 175 | 0.020 |
Why?
| | Risk | 1 | 2008 | 912 | 0.020 |
Why?
| | Alanine Transaminase | 1 | 2006 | 157 | 0.020 |
Why?
| | Child, Preschool | 1 | 2020 | 11074 | 0.020 |
Why?
| | Organ Size | 1 | 2006 | 477 | 0.020 |
Why?
| | HSP27 Heat-Shock Proteins | 1 | 2005 | 14 | 0.010 |
Why?
| | Membrane Transport Proteins | 1 | 2006 | 162 | 0.010 |
Why?
| | Case-Control Studies | 1 | 2013 | 3556 | 0.010 |
Why?
| | Cerebral Cortex | 1 | 2008 | 433 | 0.010 |
Why?
| | Quercetin | 1 | 2005 | 15 | 0.010 |
Why?
| | Pilot Projects | 1 | 2010 | 1710 | 0.010 |
Why?
| | Cytokines | 1 | 2013 | 2085 | 0.010 |
Why?
| | Intestinal Mucosa | 1 | 2010 | 623 | 0.010 |
Why?
| | Dietary Fats | 1 | 2006 | 304 | 0.010 |
Why?
| | Intensive Care Units | 1 | 2010 | 827 | 0.010 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2010 | 804 | 0.010 |
Why?
| | Transplantation, Isogeneic | 1 | 2003 | 17 | 0.010 |
Why?
| | Raffinose | 1 | 2003 | 23 | 0.010 |
Why?
| | Computational Biology | 1 | 2009 | 644 | 0.010 |
Why?
| | Allopurinol | 1 | 2003 | 63 | 0.010 |
Why?
| | Organ Preservation Solutions | 1 | 2003 | 45 | 0.010 |
Why?
| | Transcriptional Activation | 1 | 2005 | 378 | 0.010 |
Why?
| | Cell Membrane | 1 | 2006 | 738 | 0.010 |
Why?
| | Chromatography, Gas | 1 | 2002 | 33 | 0.010 |
Why?
| | Protein Binding | 1 | 2009 | 2224 | 0.010 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2004 | 243 | 0.010 |
Why?
| | Adenosine | 1 | 2003 | 225 | 0.010 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 1 | 2002 | 180 | 0.010 |
Why?
| | Trans-Activators | 1 | 2004 | 398 | 0.010 |
Why?
| | Preoperative Care | 1 | 2004 | 362 | 0.010 |
Why?
| | Gene Expression | 1 | 2006 | 1502 | 0.010 |
Why?
| | Lipopolysaccharides | 1 | 2005 | 886 | 0.010 |
Why?
| | Automation | 1 | 2000 | 95 | 0.010 |
Why?
| | Microchemistry | 1 | 2000 | 20 | 0.010 |
Why?
| | Calibration | 1 | 2000 | 146 | 0.010 |
Why?
| | Pain Measurement | 1 | 2002 | 521 | 0.010 |
Why?
| | Receptors, Interleukin-2 | 1 | 2000 | 66 | 0.010 |
Why?
| | Emulsions | 1 | 2000 | 53 | 0.010 |
Why?
| | Autopsy | 1 | 2000 | 95 | 0.010 |
Why?
| | Blood | 1 | 2000 | 107 | 0.010 |
Why?
| | Postoperative Period | 1 | 2000 | 342 | 0.010 |
Why?
| | Prospective Studies | 1 | 2010 | 7604 | 0.010 |
Why?
| | Chronic Disease | 1 | 2004 | 1793 | 0.010 |
Why?
| | Immune Tolerance | 1 | 2000 | 363 | 0.010 |
Why?
| | Regression Analysis | 1 | 2000 | 1024 | 0.010 |
Why?
| | Recombinant Fusion Proteins | 1 | 2000 | 665 | 0.010 |
Why?
| | Biopsy | 1 | 2000 | 1129 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2000 | 1946 | 0.010 |
Why?
|
|
Serkova's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|